Venatorx Pharmaceuticals to Present at IDWeek 2023
– New data to be presented from Phase 3 CERTAIN-1 study with Cefepime-Taniborbactam
– MD Anderson Cancer Center analysis of Cefepime-Taniborbactam in vitro activity against clinically significant gram-negative bacteria isolated from patients with cancer